Connection
Search Results to
This is a "connection" page, showing the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of
Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
Property | Value |
has major subject area list
|
Adaptive Immunity; Biological Products; Drug Development; Drug-Related Side Effects and Adverse Reactions; Models, Immunological
|
has minor subject area list
|
Drug Monitoring; Humans; Monitoring, Immunologic; Risk Assessment; Societies, Scientific; United States; United States Food and Drug Administration
|
information resource reference
|
Shakhnovich V, Meibohm B, Rosenberg A, Kierzek AM, Hasenkamp R, Funk RS, Thalhauser CJ, van der Graaf PH, Wang YC, Hamuro L. Immunogenicity in Clinical Practice and Drug Development: When is it Significant? Clin Transl Sci. 2020 03; 13(2):219-223.
|
label
|
Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
|